SCHEMBL21564501

SCHEMBL21564501

O=CCCc1cn(-c2ccc(-n3ccnn3)cc2)c(=O)c(N2CCOCC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.37
MAPK10 P53779 1/20 0.37
EGLN2 Q96KS0 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
EGLN3 Q9H6Z9 1/20 0.35
HIF1AN Q9NWT6 1/20 0.35
GAA P10253 1/20 0.34
ALDH1A1 P00352 4/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
NOTUM Q6P988 4/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
PDE10A Q9Y233 1/20 0.32
PIK3CA P42336 1/20 0.32
MTOR P42345 1/20 0.32
MAPT P10636 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21552839 0.91 NOTUM (0.35) NOTUMCHEK1
SCHEMBL21553092 0.88 NOTUM (0.34) ALDH1A1L3MBTL1CA12CA1CA2
SCHEMBL21564806 0.86 MAPK8 (0.37) MAPK8MAPK10EGLN2EGLN1EGLN3
SCHEMBL21552931 0.86 CMA1 (0.33) NOTUM
SCHEMBL21553052 0.86 NOTUM (0.33) NOTUM
SCHEMBL21564470 0.83 ALDH1A1 (0.41) GAAALDH1A1L3MBTL1PIK3CAMAPT
SCHEMBL21564783 0.81 PDE10A (0.39) PDE10APIK3CAMTORMAPT
SCHEMBL21564691 0.81 KDM4E (0.41) ALDH1A1L3MBTL1MAOAMAOBMAPT
SCHEMBL21564608 0.80 AKR1C3 (0.41) GAAALDH1A1L3MBTL1PIK3CAMTOR
SCHEMBL23258001 0.80 HDAC6 (0.40) GAAALDH1A1L3MBTL1PIK3CAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A MAPK8 3015/4885MAPK10 1933/4885EGLN2 185/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A MAPK8 2732/4885MAPK10 1937/4885EGLN2 172/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A MAPK8 3015/4885MAPK10 1933/4885EGLN2 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.